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LDLRAD3 is a recently defined attachment and entry receptor for Venezuelan equine
encephalitis virus (VEEV)1, a New World alphavirus that causes severe neurological
disease in humans. Here we present near-atomic-resolution cryo-electron microscopy
reconstructions of VEEV virus-like particles alone and in a complex with the
ectodomains of LDLRAD3. Domain 1 of LDLRAD3 is a low-density lipoprotein receptor
type-A module that binds to VEEV by wedging into a cleft created by two adjacent E2–
E1 heterodimers in one trimeric spike, and engages domains A and B of E2 and the
fusion loop in E1. Atomic modelling of this interface is supported by mutagenesis and
anti-VEEV antibody binding competition assays. Notably, VEEV engages LDLRAD3 in a
manner that is similar to the way that arthritogenic alphaviruses bind to the
structurally unrelated MXRA8 receptor, but with a much smaller interface. These
studies further elucidate the structural basis of alphavirus–receptor interactions,
which could inform the development of therapies to mitigate infection and disease
against multiple members of this family.

Alphaviruses are enveloped, arthropod-transmitted single-stranded
positive-sense RNA viruses that infect many vertebrate hosts, including humans, horses, rodents, birds and fish2. Alphaviruses can be
categorized on the basis of their clinical syndromes: arthritogenic
alphaviruses, such as chikungunya (CHIKV), Ross River, Sindbis
(SINV) and O’nyong-nyong, cause arthritis, polyarthralgia and
musculoskeletal-associated diseases; encephalitic alphaviruses,
including Venezuelan (VEEV), Eastern (EEEV) and Western (WEEV)
equine encephalitic viruses, cause meningitis, encephalitis and
long-term neurological sequelae in survivors. The global distribution of alphaviruses has increased in recent decades owing to international travel, expansion of mosquito vectors, deforestation and
urbanization3.
Alphaviruses enter host cells through receptor-mediated endocytosis4. Within the low-pH endosomal compartment, the virion envelope
rearranges to enable membrane fusion and nucleocapsid penetration into the cytoplasm5. The 12-kilobase alphavirus RNA genome is
released after capsid disassembly and is translated from two open
reading frames. The structural proteins (capsid, envelope glycoprotein (E)3, E2, 6K and E1) undergo processing and modification in the
endoplasmic reticulum–Golgi network. The E2 and E1 proteins facilitate
binding to entry factors and subsequent membrane fusion6–9. The E3
protein is essential for the proper folding of p62 (a precursor to E2) and
the formation of the p62–E1 heterodimer10,11 but is cleaved by furin-like
proteases during maturation12. Mature E2–E1 heterodimers assemble into trimeric spikes at the plasma membrane before budding and
release of the virion from the host cell13. The 70-nm-diameter mature
alphavirus virion comprises 240 E2–E1 heterodimers that are arranged
into 80 trimeric spikes with T = 4 icosahedral symmetry14–16. Twenty of

these trimeric spikes sit on the icosahedral three-fold (i3) symmetry
axes, and the other 60 spikes sit on the quasi-three-fold (q3) axes.
Low-density lipoprotein receptor class A domain-containing 3 (LDLRAD3) was recently identified as an attachment and entry receptor for
VEEV and shown to be essential for optimal infection in cell culture
and pathogenesis in mice1. LDLRAD3 is a conserved yet poorly characterized cell-surface protein that is expressed in neurons, epithelial
cells, myeloid cells and muscle, the endogenous ligand(s) of which
remain unknown. Biolayer interferometry experiments established that
domain 1 (D1) of LDLRAD3 (LDLRAD3(D1)) binds directly to VEEV, and
anti-LDLRAD3 antibodies and LDLRAD3(D1)–Fc fusion proteins block
VEEV attachment and infection of cells. Only VEEV uses LDLRAD3 as
a receptor, as EEEV, WEEV and other distantly related alphaviruses do
not bind to it. How LDLRAD3 engages VEEV, and why only VEEV binds
to LDLRAD3 remain unclear. We set out to address these questions
using structural, genetic and biophysical approaches.

Cryo-EM structure of LDLRAD3(D1) bound to VEEV
Mammalian-cell-expressed soluble LDLRAD3(D1) was produced in
Expi293 cells1. Cryo-electron micrographs of VEEV virus-like particles
(VLPs)17 with or without bound LDLRAD3(D1) were acquired using a
300 kV Titan Krios system equipped with a Gatan K2 detector (Extended
Data Fig. 1a and Supplementary Table 1). Single-particle analysis with
imposed icosahedral symmetry yielded reconstructions at resolutions
of 4.2 Å and 4.3 Å for the apo and complexed structures, respectively
(Fig. 1a, b and Extended Data Fig. 1b). Two-hundred and forty molecules
of LDLRAD3(D1) bound to sites on VEEV VLP (100% saturation), each one
wedged into a cleft formed between two adjacent E2–E1 heterodimers
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Fig. 1 | Cryo-EM reconstruction of VEEV VLPs in complex with LDLRAD3(D1).
a, Coloured surface representation (left) and equatorial cross-section (right) of
VEEV VLPs + LDLRAD3(D1). The surfaces are coloured by radial distance in Å,
with the density of LDLRAD3 coloured magenta. The white triangle indicates
one icosahedral asymmetric unit. The five-fold (i5), three-fold (i3) and two-fold
(i2) icosahedral axes of symmetry are indicated by a pentagon, triangles and an
oval, respectively. Trimeric spikes are labelled ‘i3’ if coincident with the i3 axes
and ‘q3’ if on a quasi-three-fold axis. The black arrows indicate the directions of
icosahedral symmetry axes (i2, i3, q3 and i5). Scale bar, 100 Å. b, c, Paired
electron density of one asymmetric unit of the VEEV–LDLRAD3 complex,
coloured by protein: E1 (grey), E2 (cyan), capsid (forest green) and LDLRAD3(D1)
(magenta) (b) or by local resolution (c). Scale bars, 20 Å.

within each trimeric spike (Fig. 1c). This cleft widens slightly when D1 of
LDLRAD3 is bound (Supplementary Video 1). Local resolution estimation performed in RELION revealed heterogenous resolution; the capsid
proteins and membrane proximal regions of the E2–E1 heterodimers
were best resolved (about 4 Å) and the membrane distal regions and
LDLRAD3(D1) were less-well resolved (about 5–6 Å) (Fig. 1d). To avoid
under- and over-sharpening of the reconstructions by conventional
global B-factor correction, post-processing was performed using DeepEMhancer18. This resulted in improved continuity and reduced noise
in the density (Extended Data Fig. 1c). The visibly clear tracing of the
carbon backbone simplified subsequent model building.

Atomic model building and refinement
LDLRAD3(D1) was identified as an LDL receptor type A (LA) domain by
the Pfam database19. LA domains are approximately 40 amino acids in
length and contain 6 disulfide-bound cysteine residues and a cluster of
conserved acidic residues that coordinate calcium ions (Fig. 2a). The
LA domain architecture is well characterized with over 200 structures
in the Protein Data Bank (PDB), revealing a highly conserved fold. The
initial model of LDLRAD3(D1) was built from its primary amino acid
sequence by threading using the SWISS-MODEL server20 with multiple
high-resolution crystal structures of related LA domains as templates.
The starting coordinates of the VEEV VLP structural proteins came from
a previously built model of the same VEEV strain (PDB: 3J0C; ref. 21). Both
models were docked into the DeepEMhancer modified electron density
of the asymmetric unit and underwent manual and computational
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Fig. 2 | Atomic model of LDLRAD3 interactions with VEEV. a, Structure-based
sequence alignment with the labelled secondary structure of various LA
domains, including mouse (m) LDLRAD3 domains 1–3, human (h) LDLR CR2 and
CR3 (PDB: 5OYL and 5OY9, respectively31), and human VLDLR-V3 (PDB: 3DPR;
ref. 33). Contact residues of LDLRAD3(D1) to the wrapped and intraspike VEEV
E2–E1 heterodimers are shaded dark and/or light purple, respectively. Contact
residues of the cysteine-rich domain 2 of LDLR (LDLR-CR2) and LDLR-CR3 to
glycoprotein G of VSV (VSV G) are shaded green and contact residues of VLDL
receptor module 3 (VLDLR-V3) to viral protein 1 (VP1) of human rhinovirus 2
(HRV2) are shaded pink, as determined by PDBePISA (www.ebi.ac.uk/pdbe/
pisa/) (Fig. 4c–e). The brackets and rectangles indicate residues that form
disulfide bonds and coordinate calcium, respectively. The figure was prepared
using ALINE33. b, Ribbon diagram of LDLRAD3(D1) and surface representation
of its wrapped and intraspike E2–E1 heterodimers. LDLRAD3(D1) and VEEV E2–
E1 are coloured by domain. LDLRAD3(D1) (purple); chain E1: DI (light grey), DII
(medium grey), DIII (dark grey) and fusion loop (FL) (orange); chain E2: A domain
(cyan), β-linker (medium blue), B domain (dark cyan) and C domain (blue). The
disulfide bonds and calcium ion in the ribbon diagram are coloured yellow and
green, respectively. c, d, Paired isolated views of electron density and a model
of LDLRAD3(D1) and its wrapped (c) or intraspike (d) heterodimers. Wrapped
refers to the E2–E1 heterodimer, the fusion loop of which is covered by
LDLRAD3. Intraspike refers to the heterodimer adjacent to the wrapped
heterodimer but within the same trimeric spike. The naming convention is
consistent with previous alphavirus–receptor structural studies23. The arrows
indicate the regions that are magnified in the insets, which contain views of
LDLRAD3(D1). Proteins are coloured by domain as described in b. N-linked
glycans are shown as balls and sticks and coloured by heteroatom. The disulfide
bonds and calcium ion are coloured yellow and green, respectively.

real-space refinement using COOT22 and PHENIX23 (Methods), with
LDLRAD3(D1) unambiguously oriented with the N terminus proximal
to the core of the virus particle (Fig. 2b–d and Supplementary Table 2).
The resultant model shows the domains and residues of the VEEV E2–
E1 heterodimers at the LDLRAD3-binding interface. The two E2–E1 heterodimers at each binding site were termed ‘wrapped’ and ‘intraspike’,
as described previously for the structure of CHIKV23 in complex with
its MXRA8 receptor. At the wrapped heterodimer interface, LDLRAD3
engages domains A and B of E2 (residues 24–28, 70–71, 166–199, 176–
177 and 223) and the fusion loop in E1 (residues 85 and 87–92). On the
intraspike heterodimer, LDLRAD3 interacts with domain A and the
β-linker of E2 (residues 5, 63–64, 79, 92–95, 148, 153–159 and 262–267;
Fig. 2c, d, Extended Data Figs. 2 and 3, and Supplementary Table 3).
The binding interface is around 900 Å2 with equal contributions from
the interfaces of the wrapped and intraspike E2–E1 heterodimers.
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Fig. 3 | Experimental assessment of the VEEV–LDLRAD3 model.
a, b, ∆B4galt7∆Ldlrad3 Neuro2a cells complemented with WT Ldlrad3 or the
indicated mutants of Ldlrad3 were inoculated with chimeric SINV–VEEV–GFP
viruses (IAB strain TrD). Subsequently (7.5 h later), the infection levels were
assessed (a) by monitoring GFP expression using FACS analysis (b). Data are
mean ± s.d. of three experiments performed in technical duplicate. Each data
symbol is the average of a technical duplicate from one experiment. n = 3.
Statistical analysis was performed using one-way analysis of variance (ANOVA);
*P = 0.0317 (N39T) or 0.0453 (R41E), **P = 0.0054, ***P = 0.001, ****P < 0.0001.
The Ldlrad3 transgene contains an N-terminal Flag tag downstream of the signal
sequence for monitoring plasma membrane expression by flow cytometry
(Extended Data Fig. 4). c, Competition binding analysis of LDLRAD3(D1)–human
Fc and anti-VEEV mouse monoclonal antibodies (3B4C-4 and TRD-14) by ELISA.
VEEV VLPs were incubated with anti-VEEV monoclonal antibodies (3B4C-4 and
TRD-14) or anti-HCV H77.39 isotype control followed by detection with
LDLRAD3(D1)–human Fc. Data are mean ± s.d. of three experiments performed
in technical triplicate. Each data symbol is the average of a technical triplicate
from one experiment. n = 3. Statistical analysis was performed using one-way
ANOVA; ***P = 0.0004; NS, not significant. OD450, optical density at 450 nm.
d, Ribbon diagram of LDLRAD3(D1) and a surface representation of its wrapped
and intraspike E2–E1 heterodimers with labelled epitopes of anti-VEEV mouse
monoclonal antibodies (3B4C-4 and TRD-14) and labelled positions of LDLRAD3
mutants. Proteins are coloured by domain. LDLRAD3(D1) (purple); chain E1: DI
(light grey), DII (medium grey), DIII (dark grey) and fusion loop (orange); chain
E2: A domain (cyan), β-linker (medium blue), B domain (dark cyan) and C domain
(blue). Inset: magnified view of the LDLRAD3(D1) ribbon diagram. The positions
of mutations that resulted in reduced VEEV infection (G33 (light yellow),
M36 (dark green), P44 (light pink) and D57 (dark blue)) are shown as balls and
sticks. The N and C termini are labelled, and the disulfide bonds and calcium ion
are coloured yellow and green, respectively.

The LDLRAD3 residues at the interaction interface that contribute to
binding of the wrapped heterodimer are 29, 34, 36, 38–44, 47, 54–57
and 62. At the intraspike heterodimer interface, residues 28–34, 42–47
and 50–52 form contacts (Supplementary Table 3).

Functional assessment of the atomic model
To assess our model, non-conservative point mutations were introduced throughout D1 of LDLRAD3 and used for complementation
674 | Nature | Vol 598 | 28 October 2021

experiments in mouse Neuro2a cells lacking Ldlrad3 (∆Ldlrad3) and
glycosaminoglycan (∆B4galt7) expression1; we performed these experiments in cells lacking glycosaminoglycans to minimize background
infection, as some alphaviruses also attach to cells through engagement
of heparan sulfate moieties17,24,25. Wild-type (WT) LDLRAD3 and single
point mutants of LDLRAD3 were transduced into ∆B4galt7∆Ldlrad3
Neuro2a cells, which were then inoculated with a chimeric, attenuated
SINV–VEEV virus that expresses the structural genes of VEEV Trinidad Donkey (TrD) such that the screen could be performed using flow
cytometry at a lower biosafety containment level (BSL2) yet with VEEV
structural proteins from a pathogenic subtype IAB isolate. Whereas
most mutant forms of LDLRAD3 promoted SINV–VEEV infection, several
(including G33D, M36T, P44R and D57V) did not support infection even
though the proteins were expressed on the cell surface at similar levels
compared to the WT form of LDLRAD3 (Fig. 3a, b and Extended Data
Fig. 4). The residues identified as loss-of-function for infectivity all sit
in a pocket of LDLRAD3 that supports direct contact with residues of
E2–E1 in both the wrapped and intraspike heterodimers (Supplementary Table 3). Several other mutations in LDLRAD3(D1) that correspond
to contact residues (including P32D, N39T, A46K and F56D) appear to
show slight increases in infectivity with normal surface expression
patterns. Although further studies are required, these changes could
enhance the affinity of VEEV binding.
Several years ago, a high-resolution cryo-electron microscopy
(cryo-EM) structure of Fab fragments of the 3B4C-4 mouse monoclonal antibody bound to VEEV was published26. 3B4C-4 binds to the
tip of the E2 B domain27 and inhibits cellular attachment and entry of
VEEV28. As the principal binding footprint (S177, V179, S180, L181, S184,
T214, N216 and K223)26 of this monoclonal antibody is proximal to the
LDLRAD3-binding site, we tested whether 3B4C-4 could inhibit binding
to LDLRAD3 using a competition binding enzyme-linked immunosorbent assay (ELISA). The 3B4C-4 monoclonal antibody was prebound to
VEEV-VLP-coated plates before addition of the LDLRAD3(D1)–human
Fc fusion protein. Notably, 3B4C-4 markedly inhibited LDLRAD3(D1)
binding, whereas another anti-VEEV monoclonal antibody (TRD-14),
which maps to a distinct epitope on the E2 B domain (G203, G204 and
T205; N. Kafai and M. Diamond, unpublished data), did not compete for
binding (Fig. 3c). A structural comparison of the monoclonal antibody
epitopes on the E2 B domain revealed that 3B4C-4 binds to residues
that are immediately adjacent to the LDLRAD3-binding site, probably
resulting in steric hindrance (Fig. 3d). By contrast, the TRD-14 epitope
is located at the distal end of the E2 B domain.

D2 does not contribute to VEEV binding
D1 of LDLRAD3 is necessary and sufficient to support infection by VEEV1,
but it remains unclear whether D2 also contributes to VEEV binding.
To evaluate this question, we expressed soluble LDLRAD3(D1+D2) in
Expi293 cells (Extended Data Fig. 5a). Electron micrographs of VEEV
VLPs with or without bound LDLRAD3(D1+D2) were acquired using
a 300 kV Titan Krios system equipped with a Falcon 4 detector (Supplementary Table 1). Single-particle analysis with imposed icosahedral
symmetry yielded a reconstruction at 5.0 Å (Extended Data Fig. 5b). The
electron density of D2 of LDLRAD3 was weak and projected away from
VEEV (Extended Data Fig. 5c). Binding of purified LDLRAD3(D1+D2)
to captured VLPs by surface plasmon resonance yielded a monovalent affinity of approximately 50 nM that was similar to LDLRAD3(D1)
(Extended Data Fig. 5d). On the basis of this structural and biophysical analysis, and previous functional data1, D2 of LDLRAD3 does not
appreciably contribute to VEEV binding or infection.
Cell culture infection experiments with mouse and human cells and
in vivo pathogenesis studies in mice defined LDLRAD3 as a cell-surface
receptor for VEEV that is required for optimal infectivity and induction
of encephalitis in mice1. Here, our single-particle cryo-EM analyses of
LDLRAD3 and VEEV VLPs provide structural insights into how VEEV
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engages with LDLRAD3 to facilitate interactions with target cells. We
observed a network of quaternary protein–protein interactions with
D1 of LDLRAD3 engaging two E2–E1 heterodimers within one trimeric spike. The specific binding determinants that we observed are
supported by structure-guided mutations that we introduced into
LDLRAD3, and binding competition studies with LDLRAD3(D1) and a
neutralizing monoclonal antibody against VEEV that engages the top
of the E2 B domain and directly blocks virus attachment. Our structures
indicate that D1 of LDLRAD3 can bind with full occupancy at four distinct sites in the icosahedral asymmetric unit of the mature VEEV VLP.
VEEV binds to LDLRAD3 in a manner that is notably similar to
the binding of CHIKV to its receptor MXRA8, which consists of two
immunoglobulin-related folds23,29,30 (Fig. 4a, b). Although LDLRAD3 and
MXRA8 have similar sites of virion engagement, LDLRAD3 forms a significantly smaller interface (about 900 Å2 versus about 2,100 Å2) even
though the monovalent affinity of virus–receptor binding is similar23
(Extended Data Fig. 5d). Inspection of the contact residues indicates
that LDLRAD3 makes greater use of hydrophobic residues to bind to
VEEV compared with the use of hydrophobic residues by MXRA8 when
binding to CHIKV (about 40% versus about 24% of interface residues,
respectively). Approximately 65% of the receptor contact positions

on VEEV spikes are shared with CHIKV (Extended Data Figs. 2 and 3).
Both receptors effectively shield the hydrophobic fusion loop from
solvent access, and all seven of the VEEV E1 contact residues are conserved with CHIKV E1. We speculate that the common positioning of
these receptors near the fusion loop might function to modulate viral
fusion during endocytosis. However, the primary contact residues
used by LDLRAD3 and MXRA8 are not conserved; notably, MXRA8 has
a substantial number of histidine residues (7% of the ectodomain) and
LDLRAD3(D1) has no histidine residues.
The distinct receptor specificities of VEEV and CHIKV can probably be
explained by the low level of sequence conservation of the E2-binding
residues (26% of 35 LDLRAD3 contact positions). Our structural analysis
also suggests why LDLRAD3 is a receptor for VEEV but not for WEEV
and EEEV—other related encephalitic alphaviruses. Other than the
aforementioned conserved contact site in the E1 fusion loop (100%
conservation for 7 residues), the receptor determinants in E2 of VEEV
generally are not conserved in WEEV and EEEV (17% and 23% identity,
respectively, for 35 contact residues; Extended Data Figs. 2 and 3). By
contrast, these determinants are essentially conserved among VEEV
complex members, which probably explains why LDLRAD3 supports
infection of all of the VEEV strains (IAB, IC and ID) that we tested1.
LDL-receptor family members mediate the entry of several viruses
belonging to different families. High-resolution structures have been
solved for LDL receptor (LDLR) LA domains in complex with vesicular
stomatitis virus (VSV) and human rhinovirus (HRV)31,32. Notably, an
unrelated negative stranded rhabdovirus (VSV) and non-enveloped
picornavirus (HRV) engage the same tryptophan residue near the
calcium-binding site of the conserved cysteine-rich domain that also
is a major contact for LDLRAD3 (Trp47) (Figs. 2a, Fig. 4c–e). Thus, evolutionarily distinct viruses have evolved similar structural strategies
for engaging related members of a protein superfamily to enable entry
into target cells. As such, it is plausible that structure-guided design of
small-molecule inhibitors could prevent entry of viruses from multiple
families.
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Methods
Recombinant LDLRAD3 protein generation and purification
Monomeric LDLRAD3 ectodomain constructs were prepared as previously described1. In brief, mouse LDLRAD3(D1) (residues 18–70) and
LDLRAD3(D1+D2) (residues 18–112) were cloned into the pCDNA3.4 vector (Thermo Fisher Scientific) with the native signal peptide sequence,
followed by an HRV 3C cleavage site (LEVLFQGP) and the mouse IgG2b
Fc region. The RAP chaperone protein (residues 1–357; GenBank:
NM_002337) was cloned into the pCDNA3.4 vector. Expi293 cells (50 ml)
were seeded at 1.5 × 106 cells per ml, then transfected with 50 µg of
LDLRAD3 and 10 µg of RAP in diluted Opti-MEM with complexed with
ExpiFectamine 293 transfection reagent (Thermo Fisher Scientific).
Cells were supplemented with ExpiFectamine 293 transfection enhancers 1 and 2 to boost transfection levels 1 d later. The supernatant was
collected 4 d after transfection. Protein was purified using protein A
Sepharose 4B (Thermo Fisher Scientific) and then dialysed into 1× HBS
with 1 mM CaCl2 and EDTA-free protease inhibitors (Roche). The cleaved
monomeric LDLRAD3 ectodomain was obtained after incubation with
HRV 3C protease (Thermo Fisher Scientific) at a 1:10 ratio overnight
at 4 °C and then purified by sequential protein A Sepharose 4B and
Superdex 75 size exclusion (GE Healthcare) chromatography in 20 mM
HEPES pH 7.4, 150 mM NaCl and 0.01% NaN3.
Cryo-EM sample preparation, data collection and
single-particle reconstruction
VEEV VLPs33 (gift from K. Carlton and J. Mascola, Vaccine Research
Center of the National Institutes of Allergy and Infectious Diseases)
with and without cleaved LDLRAD3(D1) or LDLRAD3(D1+D2) in molar
excess were flash-cooled on lacey carbon grids in liquid ethane using
an FEI Vitrobot (Thermo Fisher Scientific). Videos of the VEEV VLPs
alone and with LDLRAD3(D1) samples were recorded using the EPU
software (Thermo Fisher Scientific) using a K2 Summit electron detector (Gatan) mounted onto a Bioquantum 968 GIF Energy Filter (Gatan)
attached to a Titan Krios microscope operating at 300 keV with an
electron dose of 35 e− Å−2 and a magnification of ×105,000. Videos
of VEEV VLPs with cleaved LDLRAD3(D1+D2) were recorded using a
Falcon 4 Direct Electron Detector (Thermo Fisher Scientific) with a
magnification of ×59,000. Videos from all of the samples were corrected for beam-induced motion using MotionCor2 (ref. 34). Contrast
transfer function parameters of the electron micrographs were estimated using Gctf35, and particles were auto-picked using crYOLO36.
Single-particle analysis, specifically reference-free 2D classification,
3D refinement, video refinement, Bayesian polishing, post-processing
and local resolution estimation were performed using RELION-3.1 (ref.
37
). Post-processing of maps for model building and figure presentation was performed using DeepEMhancer18. Further information for
all of the samples is provided in Supplementary Table 1. Structural
visualization of the electron maps was performed using ChimeraX38.
Model building and refinement
The initial models of the VEEV structural proteins (E1, E2, transmembrane regions and capsid) with or without LDLRAD3 were constructed
by docking the coordinates of the previously built model of VEEV strain
TC-83 (PDB: 3J0C; ref. 21) and the model of LDLRAD3(D1) predicted by
SWISS-MODEL server20 into the electron density of the asymmetric units
of the cryo-EM maps using the fitmap command in ChimeraX. N-linked
glycans and coordinated calcium ions were built manually using COOT22.
The model underwent real-space refinement in PHENIX23 using the default
parameters plus Morphing and secondary-structure, rotamer and torsion
restraints with the initial model as the reference. Bond and angle restraints
were also applied for the modelled N-linked glycans and calcium ions.
After optimization, coordinates of the asymmetric units were checked
using MolProbity. Contact residues were identified, and buried surface
areas were calculated using PDBePISA (www.ebi.ac.uk/pdbe/pisa/).

Surface plasmon resonance
The binding kinetics and affinity of cleaved LDLRAD3(D1) or
LDLRAD3(D1+D2) to VEEV VLPs were measured using the Biacore T200
system (GE Healthcare). Experiments were performed at 30 µl min−1
and 25 °C using HBS-P (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA,
0.005% (v/v) Surfactant P20) plus 1 mM CaCl2 as running buffer. VEEV-57
monoclonal antibody (anti-VEEV E2, N. Kafai and M. Diamond, unpublished results) was immobilized onto a CM5 sensor chip (GE Healthcare)
using standard amine coupling chemistry, and VEEV VLPs were captured. LDLRAD3 proteins were injected over a range of concentrations
(1 µM to 16 nM) for 300 s, followed by a 600-s dissociation period.
The sensor chip was regenerated after each analyte concentration
with 60 s of 10 mM glycine, pH 1.7. Before the next analyte concentrated was tested, VEEV VLPs were recaptured; the response units of
captured VLPs were consistent for each cycle. All sensorgrams were
double-reference-subtracted using the reference flow cell (immobilized
VEEV-57 monoclonal antibody, no captured VLP) and the running-buffer
blank sample. The kinetic profiles and steady-state equilibrium concentration curves were fitted using a global 1:1 binding algorithm with
a drifting baseline using BIAevaluation v.3.1 (GE Healthcare).
Infection assay
A comprehensive mutation library was generated using gene synthesis
by mutating a single amino acid in D1 of the LDLRAD3 protein. The
amino acids that are essential for maintaining the structural integrity of
LDLRAD3 (the cysteines forming disulfide bonds, the amino acids coordinating the calcium and those forming the hydrophobic core) were
kept intact39. The substitutions were determined using the BLOSUM
scoring matrix40 and a list of these is provided in Supplementary Table 4.
The mutants were cloned into lentivirus vector pLV-EF1a-IRES-Hygro
(Addgene, 85134) between the BamHI and MluI restriction enzyme
sites (Genscript). An N-terminal Flag tag was added to each LDLRAD3
mutant to monitor protein expression. ∆B4galt7∆Ldlrad3 Neuro2a
cells were transduced with each LDLRAD3 mutant and, 7 d later, were
inoculated with SINV–VEEV (TrD)–GFP1 (gift of W. Klimstra, University
of Pittsburgh) infection at a multiplicity of infection of 20 for 7.5 h. Cells
were stained with anti-Flag antibodies (1:2,000 dilution, Cell Signaling
Technology, D6W5B) to measure the surface expression levels of the
WT and mutant forms of LDLRAD3. Inoculated and stained cells were
analysed using the MACSQuant Analyzer 10 (Miltenyi Biotec), and all
flow cytometry data were processed using FlowJo (FlowJo).
Competition binding ELISA
Nunc MaxiSorp plates (Thermo Fisher Scientific) were coated with
2 µg ml−1 of capture monoclonal antibody (mouse anti-VEEV-1A4A)41 in
100 µl of sodium bicarbonate coating buffer (0.1 M Na2CO3, pH 9.3) and
incubated overnight at 4 °C. Plates were washed four times with PBS and
incubated with 150 µl of blocking buffer (PBS, 4% BSA) for 1 h at room
temperature. VEEV VLPs were diluted to 1 µg ml−1 in PBS containing 2%
BSA and added (100 µl per well) to plates for 1 h at room temperature.
After four additional PBS washes, 50 µl of mouse anti-VEEV monoclonal antibody (3B4C-4 or TRD-14) at 20 µg ml−1 in PBS with 2% BSA was
added to plates for 30 min at room temperature to allow for binding
to VEEV VLPs. Then, 50 µl of human LDLRAD3(D1)–Fc at 20 µg ml−1 was
added directly, with no additional washes. One hour later, the plates
were washed four times with PBS and incubated with 100 µl per well
1:5,000 horseradish-peroxidase-conjugated goat anti-human IgG (H+L;
Jackson ImmunoResearch) diluted in PBS with 2% BSA for 1 h at room
temperature for detection of LDLRAD3(D1)–Fc binding. The plates
were washed four times with PBS and then incubated with 100 µl of
3,3′,5,5′-tetramethylbenzidine substrate (Thermo Fisher Scientific) for
3 min at room temperature before quenching by addition of 50 µl of
2 N H2SO4. Absorbance was read at an optical density of 450 nm using
the TriStar Microplate Reader (Berthold Technologies).
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Statistical analysis
Statistical significance was assigned when P < 0.05 using Prism (v.8,
GraphPad) and is indicated in each of the figure legends. Cell culture
or ELISA experiments were analysed using one-way ANOVA.
Reporting summary
Further information on research design is available in the Nature
Research Reporting Summary linked to this paper.

Data availability
All data supporting the findings of this study are available within the
paper and its Supplementary Information. All structures have been
deposited in the PDB and Electron Microscopy Data Bank databases
(PDB: 7N1I, 7N1H; EMDB: 24117, 24116, 24394). Source data are provided
with this paper.
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Extended Data Fig. 1 | Quality assessment of cryo-EM maps.
a, Representative electron micrograph (micrograph number, 1453) of VEEV
VLPs. Scale bar, 500 Å. b, Fourier shell correlation (FSC) plots for VEEV VLPs
alone (left) and with LDLRAD3(D1) (right). c, Side views of the unsharpened

(left), globally sharpened by RELION postprocessing (middle) or modified
by DeepEMhancer (right) electron densities of one asymmetric unit of
VEEV–LDLRAD3 complex. The maps are coloured by radial distance from the
VLP center, with LDLRAD3(D1) shown in purple, analogous to in Fig. 1b.
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Extended Data Fig. 2 | See next page for caption.

Extended Data Fig. 2 | Sequence alignment of E2 proteins of the VEEV
complex and other alphaviruses. Amino acid sequence alignment of E2
proteins of various VEEV strains (IAB strain TC-83, AAB02517; IAB strain TrD,
AAC19322; IC strain INH9813, AJP13627; ID strain ZPC738, AUV65225) and other
alphaviruses (EEEV strain FL93-939, ABL84687; WEEV strain CBA87, ABD98014;
SINV strain Girdwood, AUV65223; CHIKV strain 37997, ABX40011). Structurebased sequence alignments were performed between alphaviruses that do
(group 1, left margin) or do not (groups 2 and 3, left margin) use LDLRAD3 as a
receptor for infection using PROMALS3D with VEEV numbering. The figure was
prepared using ESPript 3.0. Domains are coloured (A (light cyan), B (medium
cyan), C (blue) and β linker (medium cyan)) and indicated above the sequence,

along with the secondary structure features and nomenclature (PDB: 3J0C; ref. 21).
Red boxes indicate residues that are 100% conserved; white boxes and red letters
indicate homologous residues within the specific group; white boxes and black
letters indicate non-conserved residues. Determinants of receptor binding to the
individual E2–E1 heterodimers are indicated by stars below the alignment and are
coloured magenta if specific to LDLRAD3, cyan if specific to MXRA8, or yellow if
shared between the two receptors. Wrapped denotes contacts to the wrapped
E2–E1 heterodimer, the fusion loop of which is covered by LDLRAD3(D1) or
MXRA8. Intraspike refers to the intraspike heterodimer, which is adjacent to the
wrapped heterodimer but within the same trimeric spike. Contact residues were
determined using PDBePISA.
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Extended Data Fig. 3 | See next page for caption.

Extended Data Fig. 3 | Sequence alignment of E1 proteins of the VEEV
complex and other alphaviruses. Amino acid sequence alignment of E1
proteins of various VEEV strains (IAB strain TC-83, AAB02517; IAB strain TrD,
AAC19322; IC strain INH9813, AJP13627; ID strain ZPC738, AUV65225) and other
alphaviruses (EEEV strain FL93-939, ABL84687; WEEV strain CBA87, ABD98014;
SINV strain Girdwood, AUV65223; CHIKV strain 37997, ABX40011). Structurebased sequence alignments were performed between alphaviruses that do
(group 1, left margin) or do not (groups 2 and 3, left margin) use LDLRAD3 as a
receptor using PROMALS3D with VEEV numbering. The figure was prepared
using ESPript 3.0. Domains are coloured (I (light grey), II (medium grey),
III (dark grey) and fusion loop (orange)) and indicated above the sequence, along

with the secondary structure features and nomenclature (PDB: 3J0C; ref. 21).
Red boxes indicate residues that are100% conserved; white boxes and red
letters indicate homologous residues within the specific group; white boxes and
black letters indicate non-conserved residues. Determinants of receptor
binding to the individual E2–E1 heterodimers are indicated by stars below the
alignment and are coloured magenta if specific to LDLRAD3, cyan if specific to
MXRA8 or yellow if shared between the two receptors. Wrapped denotes
contacts to the wrapped E2–E1 heterodimer, the fusion loop of which is covered
by LDLRAD3(D1) or MXRA8. Intraspike refers to the intraspike heterodimer,
which is adjacent to the wrapped heterodimer but within the same trimeric
spike. Contact residues were determined using PDBePISA.
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Extended Data Fig. 4 | Expression of LDLRAD3(D1) mutants on the cell
surface and the effect on SINV–VEEV infection. ∆B4galt7∆Ldlrad3 Neuro2a
cells complemented with indicated non-conservative point mutations of
Ldlrad3 in D1 (encoding an N-terminal Flag tag) were inoculated with chimeric
SINV–VEEV–GFP viruses (IAB strain TrD). Then, 7.5 h later, the levels of cell

surface expression of LDLRAD3 (via anti-Flag; a, c) or SINV–VEEV–GFP infection
(via GFP; b) were assessed by flow cytometry. a. Data are mean ± s.d. of three
experiments performed in technical duplicate. Each data symbol is the average
of a technical duplicate from one experiment. b, c, Representative flow
cytometry contour plots for each indicated LDLRAD3 mutant.

Extended Data Fig. 5 | D2 of LDLRAD3 does not contribute to VEEV binding.
a, Cartoon schematic of LDLRAD3 with labelled ectodomains and amino (n)
and carboxy (c) termini. D1 is coloured in a rainbow spectrum of blue to red.
b, Fourier shell correlation plots for VEEV VLP with LDLRAD3(D1+D2).
c, Electron density of one asymmetric unit of VEEV–LDLRAD3(D1+D2)
complex coloured by protein: E1 (grey), E2 (cyan), capsid (forest green) and
LDLRAD3(D1+D2) (purple). Density map viewed at a low contour level to show
weak density for D2 of LDLRAD3. A ribbon diagram of docked LDLRAD3(D1)
model is shown with the amino to carboxy termini in a rainbow spectrum of

blue to red. The cysteine residues and the acidic residues responsible for
calcium ion coordination are shown as balls and sticks. The disulfide bonds and
calcium ion are coloured yellow and green, respectively. Inset: magnified view
of LDLRAD3 with the weak density for D2 circled. d, Representative surface
plasmon resonance sensograms with the binding parameters of
LDLRAD3(D1+D2) (left) and LDLRAD3(D1) (right) to VEEV VLPs. n = 4
experiments. Data are mean + s.e.m. A 1:1 binding model (red traces) was used
to fit the experimental curves (black traces).
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Antibodies
Antibodies used

Anti-VEEV mAbs: 1A4A1-1, 3B4C-4, TRD-14, 57; Rabbit anti-FLAG antibody (Cell Signaling Technology, clone D6W5B, Cat
#14793S); horseradish peroxidase (HRP)-conjugated goat anti-human IgG (H+L; Jackson ImmunoResearch, Cat #109-035-003).

Validation

Antibodies were validated by SDS-PAGE analysis and binding to viral recombinant proteins and/or infected cells. Many of these
antibodies were sequence confirmed, generated in our laboratories, and previously used for similar applications (PMID: 33208938).
1. 1A4A-1 (Validated by SDS-PAGE analysis and binding to VEEV-infected cells and VEEV recombinant proteins); PMID: 2414905
2. 3B4C-4 (Validated by SDS-PAGE analysis and binding to VEEV-infected cells and VEEV recombinant proteins); PMID: 2414905
3. TRD-14 (Validated by SDS-PAGE analysis and binding to VEEV-infected cells and VEEV recombinant proteins); N.M.K. and M.S.D.,
unpublished
4. 57 (Validated by SDS-PAGE analysis and binding to VEEV-infected cells and VEEV recombinant proteins); N.M.K. and M.S.D.,
unpublished
5. Rabbit anti-FLAG (Cell Signaling Technology, clone D6W6B, Cat #14793S); Commercially validated by flow cytometry
6. Horseradish peroxidase (HRP)-conjugated goat anti-human IgG (H+L; Jackson ImmunoResearch, Cat #109-035-003); Commercially
validated by ELISA
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Eukaryotic cell lines
Policy information about cell lines
Cell line source(s)

Neuro-2a (Cat #CCL-131) cells were obtained from ATCC. Expi293F (Cat #A14527) cells were obtained from Thermo Fisher.

Authentication

These cells were obtained from ATCC or other commercial vendors and grew and performed as expected. Morphology of
each cell line was assessed by microscopy.
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All cell lines are routinely tested each month and were negative for mycoplasma.

Commonly misidentified lines

This study did not involve any commonly misidentified cell lines.

(See ICLAC register)

Flow Cytometry
Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
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Mycoplasma contamination

Methodology
Sample preparation

After infection, cells were harvested, fixed, permeabilized (or non-permeabilized in some experiments), and stained with the
antiviral or anti-FLAG antibodies described above.

Instrument

MACSQuant Analyzer 10

Software

FlowJo software (BD)

Cell population abundance

rans-complemented cells were analyzed for transgene expression using anti-FLAG antibody

Gating strategy

Gating was performed based on non-binding control antibodies and/or uninfected cells. Dead cells were excluded by scatter
and size.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
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